Wall Street brokerages expect Mersana Therapeutics Inc. (NASDAQ:MRSN) to post earnings of ($0.58) per share for the current quarter, according to Zacks. Five analysts have issued estimates for Mersana Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.60) and the highest estimate coming in at ($0.53). Mersana Therapeutics reported earnings per share of ($6.33) in the same quarter last year, which suggests a positive year-over-year growth rate of 90.8%. The business is scheduled to report its next quarterly earnings results on Friday, August 10th.
On average, analysts expect that Mersana Therapeutics will report full year earnings of ($2.35) per share for the current financial year, with EPS estimates ranging from ($2.58) to ($1.94). For the next fiscal year, analysts expect that the company will post earnings of ($2.31) per share, with EPS estimates ranging from ($2.55) to ($2.05). Zacks’ EPS averages are a mean average based on a survey of research firms that cover Mersana Therapeutics.
Get Mersana Therapeutics alerts:Mersana Therapeutics (NASDAQ:MRSN) last announced its quarterly earnings data on Monday, May 14th. The company reported ($0.54) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.61) by $0.07. The company had revenue of $3.06 million for the quarter, compared to analysts’ expectations of $3.49 million. Mersana Therapeutics had a negative return on equity of 124.32% and a negative net margin of 263.80%.
A number of equities analysts have commented on MRSN shares. HC Wainwright set a $33.00 price target on Mersana Therapeutics and gave the stock a “buy” rating in a research note on Monday, March 19th. Zacks Investment Research raised Mersana Therapeutics from a “hold” rating to a “buy” rating and set a $20.00 price target on the stock in a research note on Thursday, March 22nd. Cowen reaffirmed a “buy” rating on shares of Mersana Therapeutics in a research note on Monday, April 16th. Finally, ValuEngine raised Mersana Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd. Three equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $25.67.
Institutional investors have recently made changes to their positions in the business. American International Group Inc. increased its stake in Mersana Therapeutics by 110.1% in the 1st quarter. American International Group Inc. now owns 7,151 shares of the company’s stock worth $113,000 after purchasing an additional 3,747 shares during the period. TIAA CREF Investment Management LLC increased its stake in shares of Mersana Therapeutics by 1,132.7% during the fourth quarter. TIAA CREF Investment Management LLC now owns 8,037 shares of the company’s stock valued at $132,000 after buying an additional 7,385 shares during the period. California State Teachers Retirement System purchased a new position in shares of Mersana Therapeutics during the third quarter valued at approximately $142,000. The Manufacturers Life Insurance Company increased its stake in shares of Mersana Therapeutics by 505.6% during the first quarter. The Manufacturers Life Insurance Company now owns 9,496 shares of the company’s stock valued at $149,000 after buying an additional 7,928 shares during the period. Finally, Element Capital Management LLC purchased a new position in shares of Mersana Therapeutics during the first quarter valued at approximately $169,000. 75.64% of the stock is currently owned by institutional investors and hedge funds.
Mersana Therapeutics stock traded up $0.48 during trading hours on Friday, reaching $19.01. The company had a trading volume of 116,171 shares, compared to its average volume of 70,393. The stock has a market capitalization of $424.37 million and a P/E ratio of -5.90. Mersana Therapeutics has a 12-month low of $12.45 and a 12-month high of $21.01.
About Mersana Therapeutics
Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company focusing on the development of oncology therapeutics in the United States and Canada. The company develops Dolaflexin, an antibody drug conjugate (ADC) platform designed to enhance the potency and efficacy of ADCs while simultaneously enhancing the safety and tolerability.
Get a free copy of the Zacks research report on Mersana Therapeutics (MRSN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
No comments:
Post a Comment